1mr7: Difference between revisions

From Proteopedia
Jump to navigationJump to search
OCA (talk | contribs)
New page: left|200px<br /><applet load="1mr7" size="450" color="white" frame="true" align="right" spinBox="true" caption="1mr7, resolution 1.80Å" /> '''Crystal Structure of...
 
OCA (talk | contribs)
No edit summary
Line 1: Line 1:
[[Image:1mr7.gif|left|200px]]<br /><applet load="1mr7" size="450" color="white" frame="true" align="right" spinBox="true"  
[[Image:1mr7.gif|left|200px]]<br /><applet load="1mr7" size="350" color="white" frame="true" align="right" spinBox="true"  
caption="1mr7, resolution 1.80&Aring;" />
caption="1mr7, resolution 1.80&Aring;" />
'''Crystal Structure of Streptogramin A Acetyltransferase'''<br />
'''Crystal Structure of Streptogramin A Acetyltransferase'''<br />


==Overview==
==Overview==
Synercid, a new semisynthetic streptogramin-derived antibiotic containing, dalfopristin and quinupristin, is used in treatment of life-threatening, infections caused by glycopeptide-resistant Enterococcus faecium and other, bacterial pathogens. However, dissemination of genes encoding, virginiamycin acetyltransferases, enzymes that confer resistance to, streptogramins, threatens to limit the medical utility of the, quinupristin-dalfopristin combination. Here we present structures of, virginiamycin acetyltransferase D (VatD) determined at 1.8 A resolution in, the absence of ligands, at 2.8 A resolution bound to dalfopristin, and at, 3.0 A resolution in the presence of acetyl-coenzyme A. Dalfopristin is, bound by VatD in a similar conformation to that described previously for, the streptogramin virginiamycin M1. However, specific interactions with, the substrate are altered as a consequence of a conformational change in, the pyrollidine ring that is propagated to adjacent constituents of the, dalfopristin macrocycle. Inactivation of dalfopristin involves acetyl, transfer from acetyl-coenzyme A to the sole (O-18) hydroxy group of the, antibiotic that lies close to the side chain of the strictly conserved, residue, His-82. Replacement of residue 82 by alanine is accompanied by a, fall in specific activity of &gt;105-fold, indicating that the imidazole, moiety of His-82 is a major determinant of catalytic rate enhancement by, VatD. The structure of the VatD-dalfopristin complex can be used to, predict positions where further structural modification of the drug might, preclude enzyme binding and thereby circumvent Synercid resistance.
Synercid, a new semisynthetic streptogramin-derived antibiotic containing dalfopristin and quinupristin, is used in treatment of life-threatening infections caused by glycopeptide-resistant Enterococcus faecium and other bacterial pathogens. However, dissemination of genes encoding virginiamycin acetyltransferases, enzymes that confer resistance to streptogramins, threatens to limit the medical utility of the quinupristin-dalfopristin combination. Here we present structures of virginiamycin acetyltransferase D (VatD) determined at 1.8 A resolution in the absence of ligands, at 2.8 A resolution bound to dalfopristin, and at 3.0 A resolution in the presence of acetyl-coenzyme A. Dalfopristin is bound by VatD in a similar conformation to that described previously for the streptogramin virginiamycin M1. However, specific interactions with the substrate are altered as a consequence of a conformational change in the pyrollidine ring that is propagated to adjacent constituents of the dalfopristin macrocycle. Inactivation of dalfopristin involves acetyl transfer from acetyl-coenzyme A to the sole (O-18) hydroxy group of the antibiotic that lies close to the side chain of the strictly conserved residue, His-82. Replacement of residue 82 by alanine is accompanied by a fall in specific activity of &gt;105-fold, indicating that the imidazole moiety of His-82 is a major determinant of catalytic rate enhancement by VatD. The structure of the VatD-dalfopristin complex can be used to predict positions where further structural modification of the drug might preclude enzyme binding and thereby circumvent Synercid resistance.


==About this Structure==
==About this Structure==
1MR7 is a [http://en.wikipedia.org/wiki/Single_protein Single protein] structure of sequence from [http://en.wikipedia.org/wiki/Enterococcus_faecium Enterococcus faecium]. Full crystallographic information is available from [http://ispc.weizmann.ac.il/oca-bin/ocashort?id=1MR7 OCA].  
1MR7 is a [http://en.wikipedia.org/wiki/Single_protein Single protein] structure of sequence from [http://en.wikipedia.org/wiki/Enterococcus_faecium Enterococcus faecium]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=1MR7 OCA].  


==Reference==
==Reference==
Line 14: Line 14:
[[Category: Single protein]]
[[Category: Single protein]]
[[Category: Courvalin, P.]]
[[Category: Courvalin, P.]]
[[Category: Kehoe, L.E.]]
[[Category: Kehoe, L E.]]
[[Category: Murray, I.A.]]
[[Category: Murray, I A.]]
[[Category: Rafferty, J.B.]]
[[Category: Rafferty, J B.]]
[[Category: Snidwongse, J.]]
[[Category: Snidwongse, J.]]
[[Category: left-handed parallel beta-helix domain]]
[[Category: left-handed parallel beta-helix domain]]


''Page seeded by [http://ispc.weizmann.ac.il/oca OCA ] on Tue Nov 20 21:38:53 2007''
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Thu Feb 21 13:58:12 2008''